title: Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma.
abstract: BACKGROUND
  Proinflammatory leukotrienes, which are not completely inhibited by inhaled corticosteroids, may contribute to asthmatic problems [corrected]. A 16 week multicentre, randomised, double blind, controlled study was undertaken to study the efficacy of adding oral montelukast, a leukotriene receptor antagonist, to a constant dose of inhaled budesonide.
  
  
  METHODS
  A total of 639 patients aged 18-70 years with forced expiratory volume in 1 second (FEV(1)) > or =55% predicted and a minimum predefined level of asthma symptoms during a 2 week placebo run in period were randomised to receive montelukast 10 mg (n=326) or placebo (n=313) once daily for 16 weeks. All patients received a constant dose of budesonide (400-1600 microg/day) by Turbuhaler throughout the study.
  
  
  RESULTS
  Mean FEV(1) at baseline was 81% predicted. The median percentage of asthma exacerbation days was 35% lower (3.1% v 4.8%; p=0.03) and the median percentage of asthma free days was 56% higher (66.1% v 42.3%; p=0.001) in the montelukast group than in the placebo group. Patients receiving concomitant treatment with montelukast had significantly (p<0.05) fewer nocturnal awakenings and significantly (p<0.05) greater improvements in beta agonist use and morning peak expiratory flow rate (PEFR).
  
  
  CONCLUSIONS
  For patients with mild airway obstruction and persistent asthma symptoms despite budesonide treatment, concomitant treatment with montelukast significantly improves asthma control.
authors.affiliation: Merck Sharp & Dohme, c/Josefa Valcarcel 38, 28027 Madrid, Spain. maria_jose_vaquerizo@merck.com
authors.forename: M J
authors.initials: MJ
authors.lastname: Vaquerizo
authors.forename: P
authors.initials: P
authors.lastname: Casan
authors.forename: J
authors.initials: J
authors.lastname: Castillo
authors.forename: M
authors.initials: M
authors.lastname: Perpiña
authors.forename: J
authors.initials: J
authors.lastname: Sanchis
authors.forename: V
authors.initials: V
authors.lastname: Sobradillo
authors.forename: A
authors.initials: A
authors.lastname: Valencia
authors.forename: H
authors.initials: H
authors.lastname: Verea
authors.forename: J L
authors.initials: JL
authors.lastname: Viejo
authors.forename: C
authors.initials: C
authors.lastname: Villasante
authors.forename: J
authors.initials: J
authors.lastname: Gonzalez-Esteban
authors.forename: C
authors.initials: C
authors.lastname: Picado
mesh_terms: D000085:Acetates / Q000008:administration & dosage* / Q000009:adverse effects; D000280:Administration, Inhalation; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D019819:Budesonide / Q000008:administration & dosage* / Q000009:adverse effects; D003521:Cyclopropanes; D004359:Drug Therapy, Combination; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D011804:Quinolines / Q000008:administration & dosage* / Q000009:adverse effects; D013440:Sulfides; D016896:Treatment Outcome
chemical_list: D000085:Acetates; D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D003521:Cyclopropanes; D011804:Quinolines; D013440:Sulfides; D019819:Budesonide; C093875:montelukast